Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
55
days
Efficacy and safety of golimumab biosimilar BAT2506 in patients with active psoriatic arthritis after switching from reference golimumab: 52-week results of a phase 3, double-blind, randomized study
AuthorsHonghu Tang; Eva Dokoupilova; Bogdan Batko; Marek Zawadzki; Anastas Batalov; Yi Liu; Xiaolei Yang; Yinbo Zhou; Qingfeng Dong; Yi Liu
Affiliations1. West China Hospital of Sichuan University; 2. Medical Plus, s.r.o; 3. Malopolskie Badania Kliniczne Sp. z o.o; 4. Reum-Medica S. C. Bozena Kowalewska, Marek Zawadzki; 5. University Hospital “Kaspela”, Medical University of Plovdiv; 6. Bio-Thera Solutions Ltd
118
days
Beyond the first switch: multiple switching, cross-switching, and nocebo-aware implementation of biosimilars in real-world care in non-US health systems
AuthorsAhmad Z. Al Meslamani; Anan S. Jarab; Husam El Sharu; Khadeijah Ahmed Al Marshoodi
Affiliations1. Al Ain University; 2. Jordan University of Science and Technology; 3. Case Western Reserve University; 4. University of Sharjah
145
days
Exploring the potential benefits of allergen immunotherapy beyond respiratory allergy
AuthorsSimone Foti Randazzese; Salvatore Barberi; Riccardo Castagnoli; Francesco Catamerò; Lorenzo Cosmi; Sara Guiducci; Lorenzo Lodi; Francesca Mori; Ivan Taietti; Sara Manti; Mattia Giovannini
Affiliations1. University of Pavia; 2. Fondazione IRCCS Policlinico San Matteo; 3. ASST-Rhodense, RHO; 4. Meyer Children’s Hospital IRCCS; 5. University of Florence; 6. University of Messina
54
days
Combining biological matrices with growth factor concentrates: toward standardized protocols in regenerative medicine
AuthorsEduardo Anitua; María Troya; Roberto Tierno; Francisco Muruzabal; Mohammad H. Alkhraisat
Affiliations1. BTI-Biotechnology Institute; 2. University Institute for Regenerative Medicine & Oral Implantology, UIRMI (UPV/EHU-Fundación Eduardo Anitua); 3. University of Jordan
87
days
Expanding indications of immune checkpoint inhibitors: a decade of success going strong
AuthorsVictor M. Samperio; Ruba Alchaikh Hassan; Aishwarya Ghonge; Constantin A. Dasanu
Affiliations1. Eisenhower Health; 2. Christus Health
44
days
Is incretin therapy the missing link to silencing residual inflammation in biologic-treated psoriasis?
AuthorsEva Klara Merzel Šabović; Miodrag Janić
Affiliations1. University Medical Centre Ljubljana; 2. University of Ljubljana
91
days
Patient-centered approaches in psoriasis management: lessons from the past and future directions
AuthorsVictoria McGuirt; Jake Breimann; Aarushi Gulati; William Huang; Steven Feldman
Affiliations1. Wake Forest University School of Medicine; 2. Lewis Katz School of Medicine at Temple University; 3. A. T. Still University School of Osteopathic Medicine in Arizona; 4. University of North Carolina at Chapel Hill
105
days
Gene therapy approaches for inborn errors of immunity: from bench to bedside
AuthorsJasmeen Dara; Claire Booth
Affiliations1. UCL Great Ormond Street Institute of Child Health; 2. Great Ormond Street Hospital
45
days
Originator versus biosimilar adalimumab in hidradenitis suppurativa: a real-world cohort study
AuthorsAbdullah Demirbaş; Mustafa Esen; Esin Diremsizoğlu; Gözde Ulutaş Demirbaş
Affiliations1. Kocaeli University Faculty of Medicine; 2. Dicle University Faculty of Medicine; 3. Kocaeli City Hospital
63
days
Twelve-month changes in lipid-derived cardiovascular risk indices among patients with psoriasis receiving biologic therapy: a multicenter real-world retrospective cohort study
AuthorsBahadır Aslancan; Nur Ecer; Ayşegül Tel Kankılıç; Ömer Karakoyun; Kadir Kaya
Affiliations1. Şanlıurfa Training and Research Hospital; 2. Gazi Yaşargil Training and Research Hospital; 3. Ergani State Hospital; 4. Istinye University Hospital Medical Park Gaziosmanpaşa
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days